The European healthcare CDMO market is estimated to grow significantly during the forecast period. The evolvement of the drug outsourcing business, in order to reduce the time and cost of many processes previously accomplished in-house and is continuously fuelling the growth of the healthcare CDMO market in Europe. Moreover, the prevalence of chronic diseases is supporting the demand for generic drugs. Owing to this, the major pharmaceutical companies are expressively outsourcing the generic drug development process to contract manufacturers. This, in turn, is aiding the pharmaceutical companies to focus on the R&D of new drugs for chronic diseases and further propels the market growth. 

 The European market for healthcare CDMO is segregated on the basis of services and region. Based on services, the market is further classified into contract development and contract manufacturing. The contract manufacturing services segment is projected to have a significant share in the European healthcare CDMO market owing to the significant adoption of outsourcing services by pharmaceutical companies across the globe. The contract development services are further classified into clinical, preclinical, and laboratory services. The clinical segment is projected to have significant growth in the market owing to increasing clinical research. 

Moreover, the contract manufacturing services segment is further classified into API, finished dosage formulations, and medical devices. The API contract manufacturing services segment is significantly contributing to the growth of the market during the forecast period. Based on geography, the European healthcare CDMO market is further segregated into the UK, Germany, France, Italy, Spain, and the Rest of Europe. UK is projected to have a considerable share in the European healthcare CDMO market owing to significant investment in drug discovery and development in the country.  

The companies which are contributing to the growth of the European healthcare CDMO market include Almac Group Ltd., B. Braun Melsungen AG, Boehringer Ingelheim International GmbH, Jubilant Life Sciences Ltd., Lonza Group Ltd., Recipharm AB, and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market. 

Research Methodology

The market study of the European healthcare CDMO market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for pharmaceutical and medical device companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. European Healthcare CDMO Market Research and Analysis by Services

The Report Covers

• Comprehensive research methodology of the European healthcare CDMO market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European healthcare CDMO market.
• Insights about market determinants that are stimulating the European healthcare CDMO market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.